Dendreon Corp

Dendreon — Merger or Acquisition (July 2003)

39 slides from Dendreon's merger presentation, Jul 7, 2003

  1. Slide 1: Building a Premier Biotechnology Company

    Dendreon Corporation Corvas International Building a Premier Biotechnology Company

  2. Slide 2: Forward-Looking Statement Disclaimer

    Forward-Looking Statement Disclaimer This presentation includes forward-looking statements, including statements about Dendreon’s proposed acquisition of Corvas, post-closing business synergies and product opportunities, and product development and commercialization. Actual results may differ materi

  3. Slide 3: Additional Information About the Acquisition and Where to Find It

    Additional Information About the Acquisition and Where to Find It Dendreon and Corvas have filed with the Securities and Exchange Commission (“SEC”) a Registration Statement on Form S-4, which contains a joint proxy statement/prospectus with respect to the combination and other relevant materials. I

  4. Slide 4: Dendreon Corporation

    Dendreon Corporation Developing targeted therapies for the treatment of cancer • Immunotherapeutic cancer programs -Provenge®, MylovengeTM, APC8024, Trp-p8, NY-ESO, CEA, MN, Telomerase • Monoclonal antibodies and small molecules -Trp-p8, DN1921, DN1924 • Industry leading collaborators -Genentech, In

  5. Slide 5: Momentum Continues in 2003

    . Momentum Continues in 2003 Corvas Acquisition • Stock for stock transaction • Valued to $73 M, based on Dendreon closing stock price of $5.79 on 2/24/03, an 83% premium to Corvas’ stock price as of the same date • Dendreon stockholders will own 71.6% and Corvas stockholders will own 28.4%, based o

  6. Slide 6: Combining Strengths

    Combining Strengths Technology • Broad oncology portfolio covering 4 platforms • 5 ongoing clinical programs • Enhanced intellectual property estate, 87 issued U.S. patents • Small molecule, medicinal chemistry expertise Operations • Experienced management team • Clinical development expertise • Res

  7. Slide 7: Breadth in Oncology

    Breadth in Oncology Vaccine Targets Antibodies Small Molecules Prodrug Program NY-ESO Trp-p8 Trp-p8 uPA CEA DN1924 Urokinase (uPA) Inhibitors Other Serine Proteases MN DN1921 (autoimmune diseases) Matriptase Inhibitors Telomerase Serine Protease Inhibitors Trp-p8 ARF DNDN CVAS

  8. Slide 8: Advanced Clinical Trial Pipeline

    Advanced Clinical Trial Pipeline Product/Target Phase 1 Phase 2 Phase 3 Provenge ® Androgen Independent Prostate Cancer Completed D9901 D9902 Androgen Dependent Prostate Cancer P-11 (Provenge alone) P-16 (Provenge+Avastin) Mylovenge ™ Multiple Myeloma rNAPc2 Acute Coronary Syndromes APC8024 Breast,

  9. Slide 9: Leading Cancer Vaccine Platform

    Leading Cancer Vaccine Platform • Well validated and well characterized antigen targets manufactured as recombinant proteins • Proprietary Antigen Delivery Cassette TM technology • Induces strong and reproducible immune responses

  10. Slide 10: Provenge Phase 3 Trial (D9901)

    Provenge ® Phase 3 Trial (D9901) Double Blind, Placebo Controlled Vaccinate at Weeks 0 2 4 • First randomized, double blind, placebo controlled Phase 3 study of a cancer vaccine • Primary endpoint – Median time to objective disease progression • Advanced androgen independent prostate cancer patients

  11. Slide 11: Primary Efficacy Analysis (ITT)

    Primary Efficacy Analysis (ITT) Time from randomization to disease progression Provenge (n=82) Placebo (n=45) p=0.085 HR=1.394 (95% CI 0.953 - 2.037) Proportion Without Progression Time to Disease Progression (weeks) Phase 3 Trial #D9901

  12. Slide 12: Gleason Score

    Gleason Score • Routinely performed prostate grading system - Histologic measure of aggressiveness of tumor - Patients with score of £ 7 tend to have better prognosis • Majority (75%) of androgen independent patients have a score of 7 or less • Pre-specified subgroup for analysis • Single most impor

  13. Slide 13: Efficacy Analysis: Gleason

    Efficacy Analysis: Gleason £ 7 Time to objective disease progression (Kaplan-Meier method): Primary Efficacy Analysis, Gleason Score £ 7, Intent-to-Treat Patients Provenge (n=50) Placebo (n=25) P=0.002 HR=2.222 (95% Cl: 1.331 – 3.710) Proportion Progression Free Time (weeks) Phase 3 Trial #D9901

  14. Slide 14: Comparison of Gleason Subgroups

    Comparison of Gleason Subgroups Subgroup Analysis: Gleason £ 7 Subgroup Analysis: Gleason ³ 8 Provenge (n=50) Placebo (n=25) Provenge (n=32) Placebo (n=20) log rank p=0.002 log rank p=0.043 Proportion Progression Free Time (weeks) Proportion Progression Free Time (weeks) Phase 3 Trial #D9901

  15. Slide 15: Progression Analysis: Gleason

    Progression Analysis: Gleason £ 7 Time to Progression (weeks) Provenge (N=50) Placebo (N=25) Treatment Effect Median 16.0 9.0 1.78 Progression Free Survival Rate (percent) Months Provenge Placebo Treatment Effect 34.7 4.0 8.7 17.7 4.0 4.4 10.1 >10.1 6.7 > 6.7 Phase 3 Trial #D9901

  16. Slide 16: Secondary Endpoint

    Secondary Endpoint Time to Onset of Disease-Related Pain (Gleason £ 7 and ³ 8) Gleason £ 7 Gleason ³ 8 [CHART] [CHART] Phase 3 Trial #D9901

  17. Slide 17: Provenge Very Well Tolerated

    Provenge Very Well Tolerated* APC8015 (n=82) Placebo (n=45) Median Duration (days) Event [n(%)] Rigor 49 (59.8) 3 (6.7) 1.0 Pyrexia 24 (29.3) 1 (2.2) 2.0 Headache NOS 11 (13.4) 1 (2.2) 1.0 Paresthesia 11 (13.4) 1 (2.2) 2.0 Dyspnea 9 (11.0) 1 (2.2) 1.0 Number (%) of patients with Adverse Events *Occu

  18. Slide 18: Provenge Trial D9902B

    Provenge Trial D9902B • Special Protocol Assessment received from FDA – D9902B will serve as basis for BLA application • Trial enrolling AIPC patients with Gleason score £ 7 • Approximately 275 patients will be enrolled into study to support BLA

  19. Slide 19: Provenge Collaboration Discussions

    Provenge Collaboration Discussions • Discussions progressing as planned • Large market, data and regulatory plan have driven interest • Competitive process • Will be structured as co-development and co-promotion agreement • Global agreement minus Asia and Oceania

  20. Slide 20: APC8024 Phase Trials

    APC8024 Phase 1 Trials Patient Population • 18 patients enrolled; 16 evaluated • Advanced, metastatic breast cancer patients • Her-2 positive (2+, 3+) • Failed multiple courses of chemotherapy including 15/16 who failed Herceptin • Historical median time to progression 3-6 months Endpoints • Safety

  21. Slide 21: APC8024 Clinical Response

    APC8024 Clinical Response Clinical Benefit 25% (4/16 patients evaluated) Partial Response*: 1 patient, lasting more than 25 weeks Ongoing Stable Disease: 1 patient stable 48+ weeks 2 patients stable for more than one year No significant side effects reported, no evidence of any cardio toxicity * As

  22. Slide 22: Dendreon & Genentech: Trp-p8 Collaboration

    Dendreon & Genentech Trp-p8 Collaboration

  23. Slide 23: Trp-p8 Characteristics

    Trp-p8 Characteristics • Trans-membrane voltage gated Ca2 + channel • Over-expressed in breast, prostate, lung and colon cancers as well as hyperplastic prostate • Multiple therapeutic opportunities - Vaccines - Monoclonal antibodies - Small molecules References: U.S. Patent 6,194,152: Prostate tumo

  24. Slide 24: In Normal Human Tissue, Trp-p8 Expression is Restricted to the Prostate

    In Normal Human Tissue, Trp-p8 Expression is Restricted to the Prostate [CHART]

  25. Slide 25: Trp-p8 is Detected in Primary Cancer Samples by In Situ Hybridization

    Trp-p8 is Detected in Primary Cancer Samples by In Situ Hybridization Tissue Type Prostate Adeno Ca Breast Adeno Ca Melanoma Colorectal Adeno Ca Lung Ca Number of samples positive/studied Normal Breast Tissue Breast/CA RNA Tissue [GRAPHIC] Normal Colon Tissue Colon/CA RNA Tissue [GRAPHIC]

  26. Slide 26: Trp-p8 – Architecture

    Trp-p8 – Architecture

  27. Slide 27: Genentech Trp-p8 Collaboration

    Genentech Trp-p8 Collaboration • Structured as a co-development, co-promotion agreement with profit sharing rights in the U.S. • Significant upfront and milestone payments • Genentech responsible for manufacturing and funds majority of manufacturing and clinical trial costs • Leverage Corvas’ medici

  28. Slide 28: Collaboration Milestones

    Collaboration Milestones • Equity purchases and cash milestone payments • Milestone Events - At deal signing - Drug candidate identification - IND filing - Clinical trial milestones - BLA submission - BLA approvals • Total milestone payments could exceed $110 Million

  29. Slide 29: Corvas Oncology Programs

    Corvas Oncology Programs Dendreon Corporation Corvas International

  30. Slide 30: Serine Protease Cancer Programs

    Serine Protease Cancer Programs • Relevant for prostate cancer • Most well known is PSA • Provide a number of therapeutic opportunities - Inhibition with small molecules or monoclonal antibodies - As a target for monoclonal antibodies and therapeutic vaccines - Leverage enzymatic activity for delive

  31. Slide 31: Protease Activated Cancer Therapy (PACT) Program

    Protease Activated Cancer Therapy (PACT) Program [GRAPHIC]

  32. Slide 32: CVS-10290 PK—Acute dose

    CVS-10290 PK—Acute dose of 25mg/kg CVS-10290, IP in DU145 bearing nude mice • Dox peaks at 4 hours in tumors • At 24 hours dox is still detectable in tumors JB017 25mg/kg CVS-10290 PK in nude mice/DU145 tumors JB017 25mg/kg CVS-10290 PK in nude mice/DU145 tumors [CHART] [CHART]

  33. Slide 33: CVS-10290 Efficacy Study Q1dx5

    CVS-10290 Efficacy Study Q1dx5 DU145 Tumor Volume Rx Q1 Dx5 d0-4 (imp -29) [CHART] Dose Group max group % body weight loss % Tumor growth inhibition t test (p-value) Control - Dox 1.0mg/kg -12% 0.1980 3/10 toxic deaths CVS-10290 20mg/kg -9% 0.0112

  34. Slide 34: Corvas Cardiovascular Program

    Corvas Cardiovascular Program Dendreon Corporation Corvas International

  35. Slide 35: rNAPc2 Potent Anticoagulant

    rNAPc2 Potent Anticoagulant • Acts at initiation of coagulation cascade by blocking Tissue Factor/Factor VIIa complex • Produces sustained suppression of thrombin generation – a key element in acute coronary syndrome (ACS) • Potent and prolonged duration of action • May complement downstream product

  36. Slide 36: Pro Forma Balance Sheet

    Pro Forma Balance Sheet Quarter Ending March 31, 2003 ($ in millions) Pro Forma Cash, cash equivalents, short-term & long-term investments $133.8 Working capital 88.7 Total assets 143.6 Total stockholders’ equity 107.6

  37. Slide 37: Expected Milestones and News Flow

    Expected Milestones and News Flow Type 2003 2004 2005 Clinical Data Presentations at upcoming scientific meetings. Regulatory Fast track designation — Provenge Preclinical Milestone Trp-p8 Mab lead selection and DNA milestone payment Clinical Trials Complete Phase II Mylovenge studies Clinical Trial

  38. Slide 38: The New Dendreon

    The New Dendreon • Creating a top tier biotech company • Validated therapeutic cancer platform - Near-term market opportunities - Significant clinical benefit demonstrated with Provenge ® • Broad portfolio includes vaccines, monoclonal antibodies, small molecules and prodrugs • Industry leading part

  39. Slide 39: Dendreon Corporation

    Dendreon Corporation © Dendreon 2003

Dendreon — Merger or Acquisition (July 2003) on 6ix